{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:57:27Z","timestamp":1794581847432,"version":"4.9.1"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of the analysis was to evaluate if 10\u2009mg naloxone, administered intramuscularly, could reverse or prevent opioid\u2010induced respiratory depression (OIRD), including OIRD associated with the administration of lethal doses of high\u2010potency opioids. A naloxone population pharmacokinetic (PK) model was generated using data from two naloxone auto\u2010injector (NAI) clinical PK studies. Mechanistic OIRD PK\u2010pharmacodynamic (PD) models were constructed using published data for buprenorphine, morphine, and fentanyl. Due to the lack of published carfentanil data in humans, interspecies allometric scaling methods were used to predict carfentanil PK parameters in humans. A PD model of a combined effect\u2010compartment and receptor kinetics model with a linear relationship between ventilation and carbon dioxide was used to predict the respiratory depression induced by carfentanil. Model\u2010based simulations were performed using the naloxone population PK model and the constructed mechanistic OIRD PK\u2013PD models. Changes in ventilation were assessed after opioid exposure and treatment with 2\u2009mg naloxone or one or two doses of 10\u2009mg naloxone. A higher percentage of subjects recovered back to the rescue ventilation thresholds and\/or had a faster recovery to 40% or 70% of baseline ventilation with 10\u2009mg compared with 2\u2009mg naloxone. A second dose of 10\u2009mg naloxone, administered 60\u2009min post\u2010opioid exposure, expedited recovery to 85% of baseline ventilation and delayed time to renarcotization compared with a single dose. In addition, when 10\u2009mg naloxone was administered at 5, 15, 30, or 60\u2009min before fentanyl or carfentanil exposure, rapid and profound OIRD was prevented.<\/jats:p>","DOI":"10.1002\/psp4.13215","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:42:01Z","timestamp":1726504921000},"page":"1722-1733","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanistic pharmacokinetic\u2013pharmacodynamic modeling and simulations of naloxone auto\u2010injector 10\u2009mg reversal of opioid\u2010induced respiratory depression"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2433-8989","authenticated-orcid":false,"given":"Tae Eun","family":"Yang","sequence":"first","affiliation":[{"name":"Parexel International Clinical Pharmacology, Modeling &amp; Simulation  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-2940","authenticated-orcid":false,"given":"Francesca","family":"Del\u00a0Bene","sequence":"additional","affiliation":[{"name":"Parexel International Clinical Pharmacology, Modeling &amp; Simulation  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-591X","authenticated-orcid":false,"given":"Silvia Maria","family":"Lavezzi","sequence":"additional","affiliation":[{"name":"Parexel International Clinical Pharmacology, Modeling &amp; Simulation  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iavarone","sequence":"additional","affiliation":[{"name":"Parexel International Clinical Pharmacology, Modeling &amp; Simulation  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Parexel International Clinical Pharmacology, Modeling &amp; Simulation  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kim","sequence":"additional","affiliation":[{"name":"Parexel International Clinical Pharmacology, Modeling &amp; Simulation  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanne","family":"Gjurich","sequence":"additional","affiliation":[{"name":"kaleo, Inc.  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kessler","sequence":"additional","affiliation":[{"name":"kaleo, Inc.  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6905a2"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0625-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks078"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1158479"},{"key":"e_1_2_10_6_1","unstructured":"U.S. Department of Health and Human Services.What Are Opioids?Prevent Opioid Abuse and Addiction.https:\/\/www.hhs.gov\/opioids\/prevention\/index.html. Accessed April 28 2020."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181c38c25"},{"key":"e_1_2_10_8_1","unstructured":"International Medication Systems Limited's Naloxone Hydrochloride Injection USP.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d2f5bfa0\u2010933e\u201046d0\u20108b1a\u20109f90e6aaba54. Accessed January 20 2023."},{"key":"e_1_2_10_9_1","unstructured":"Emergent Devices Inc.'s NARCAN\u00ae (naloxone hydrochloride) nasal spray.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=724df050\u20105332\u20104d0a\u20109a5f\u201017bf08a547e1. Accessed July 29 2023."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234683"},{"key":"e_1_2_10_11_1","unstructured":"KLOXXADO\u2122Hikma Speciality USA Inc.'s KLOXXADO\u2122 (naloxone hydrochloride) nasal spray Prescribing Information (Hikma Specialty USA Inc.). National Library of Medicine DailyMed.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ebf0f833\u2010c1c0\u2010487c\u20108f29\u201001fa8c61b6cb. Accessed September 9 2023."},{"key":"e_1_2_10_12_1","unstructured":"ZIMHI\u2122USWM LLC's ZIMHI\u2122 (naloxone hydrochloride injection)(USWM LLC). National Library of Medicine DailyMed.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=52e49022\u20109172\u20104da3\u2010ba83\u20105995cacca9fb. Accessed September 9 2023."},{"key":"e_1_2_10_13_1","unstructured":"NALOXONE HYDROCHLORIDE INJECTION USP AUTO\u2010INJECTOR \u2013 naloxone hydrochloride injection solution(kaleo Inc.). National Library of Medicine DailyMed.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b5463553\u2010b775\u201047a3\u20108d10\u201031e01ca1ec72. Accessed September 9 2023."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746110-00004"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181d5e29d"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100025"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b04872"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/53.12.1337"},{"key":"e_1_2_10_19_1","unstructured":"FeaselM RandallWR.The use of in\u00a0vitro and in silico technologies for predicting human pharmacology and toxicology of carfentanil.2017.http:\/\/hdl.handle.net\/10713\/6764. Accessed March 1 2021."},{"key":"e_1_2_10_20_1","unstructured":"GitHub \u2010 FDA\/Mechanistic\u2010PK\u2010PD\u2010Model\u2010to\u2010Rescue\u2010Opioid\u2010Overdose. Version 1.0.https:\/\/github.com\/FDA\/Mechanistic\u2010PK\u2010PD\u2010Model\u2010to\u2010Rescue\u2010Opioid\u2010Overdose. Accessed April 30 2021 and June 22 2021."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2020.02.008"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000000400"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/57.2.192"},{"key":"e_1_2_10_24_1","unstructured":"FDA Center for Drug Evaluation and Research Summary Basis of Approval Clinical Pharmacology and Biopharmaceutics Review for NDA 215457.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215457Orig1s000ClinPharmR.pdf. Accessed June 4 2024."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2016.07.002"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2117"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2010.00256.x"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.13215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T13:40:01Z","timestamp":1729604401000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.13215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/psp4.13215"],"URL":"https:\/\/doi.org\/10.1002\/psp4.13215","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"2024-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}